44 vacatures voor Johnson Johnson in Leiden, Zuid-Holland, Nederland (2024)

FAQs

What is Johnson and Johnson in trouble for? ›

June 3 (Reuters) - Johnson & Johnson (JNJ.N) , opens new tab must pay $260 million to an Oregon woman who said she got mesothelioma, a deadly cancer linked to asbestos exposure, from inhaling the company's talc powder, a jury found on Monday.

The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.

The company ranks #2 on the Pharmaceutical Industry list and #27 on the overall Top 50 All-Stars list. Johnson & Johnson's mission statement, Our Credo, continues to be the backbone of the company as it delivers on its commitment to tackling the world's toughest health challenges.

Based on the April 2023 settlement offer and previous settlements reached in verdicts, our Talcum Powder Attorneys estimate that Talcum Powder Lawsuits could settle for anywhere between $100,000 and $1 million. These estimates are by no means a guarantee of financial compensation for Talcum Powder Lawsuits.

In a May 2024 proposal, Johnson & Johnson offered a $6.48 billion talcum powder lawsuit settlement to plaintiffs in federal litigation claiming the company's talcum powder caused them to develop ovarian cancer. Courts have also awarded billions of dollars in previous talcum powder lawsuit verdicts.

No one owns a majority of Johnson & Johnson. The healthcare company's top shareholder is The Vanguard Group, at 9.5%.

Johnson & Johnson has an overall rating of 4.1 out of 5, based on over 16,769 reviews left anonymously by employees. 84% of employees would recommend working at Johnson & Johnson to a friend and 76% have a positive outlook for the business. This rating has decreased by 1% over the last 12 months.

Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales - $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.

Johnson & Johnson acquired Pfizer's consumer healthcare business, expanding the company's capacity to meet rising global needs.

Who is Johnson and Johnson's biggest competitor? ›

The main competitors of Johnson & Johnson include Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Corcept Therapeutics (CORT).

James Wittenborn Johnson (born 1979) is an American heir, filmmaker, and socialite. He is a great-grandson of Robert Wood Johnson I (co-founder of Johnson & Johnson).

Johnson & Johnson was awarded highest honors at the 1893 Chicago World's Fair, and earned a special diploma for the health care innovations it exhibited: sterile surgical dressings, sterile sutures and medicated plasters. Fred Kilmer – scientist, innovator, New Jersey Microscopical Society member!

The company is no stranger to lists that honor top companies. For the 22nd year in a row, the company was recently named a 2024 Fortune World's Most Admired Company. Johnson & Johnson is honored to be named on Fortune's 2024 America's Most Innovative Companies list.

New Brunswick, NJ

Johnson & Johnson / Headquarters

The April 2024 ruling was made after the woman's family filed a lawsuit claiming that J&J's talc-based product was contaminated with asbestos which led to her mesothelioma diagnosis. In April 2023, Johnson & Johnson proposed an $8.9 billion trust fund to settle its talc lawsuits.

A subsidiary of Johnson & Johnson is now proposing paying approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc caused ovarian cancer.

J&J's iconic talc-based baby powder has been linked to cancer due to alleged asbestos contamination. The company has been hit with lawsuits from 40,000 cancer patients. Disturbingly, evidence suggests that J&J knew about the asbestos contamination as early as 1972 but failed to notify the FDA.

In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.